B003 in Patients With HER2-positive Recurrent or Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer
Interventions: BIOLOGICAL: Recombinant anti-HER2 humanized monoclonal antibody conjugate for injection.R&D code: B003.
Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd